• Explore /
  • Poster
  • / Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with pembrolizumab, in patients with neuroendocrine carcinoma.

Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with pembrolizumab, in patients with neuroendocrine carcinoma.

Abstract Poster

Authors

Patrick McGarrah

Patrick Walsh McGarrah

Mayo Clinic, Rochester, MN;

Patrick Walsh McGarrah , Shruthi Naik , Thorvardur Ragnar Halfdanarson , Konstantinos Leventakos , Kah Whye Peng , Stephen J. Russell , Alex A. Adjei , Julian R. Molina

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03647163

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS657)

DOI

10.1200/JCO.2023.41.4_suppl.TPS657

Abstract #

TPS657

Poster Bd #

P10

Abstract Disclosures

Similar Posters

First Author: Patrick Walsh McGarrah

First Author: Amin Nassar

First Author: Daniel Olson

Poster

2023 ASCO Annual Meeting

Safety of checkpoint inhibitors in older patients with genitourinary cancers.

Safety of checkpoint inhibitors in older patients with genitourinary cancers.

First Author: Brian Hemendra Ramnaraign